HAIFA, Israel, June 25, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has selected rotator cuff repair as the second indication in its orthopedic clinical program. The Company’s PLacental eXpanded (PLX) cells offer potential as the first off-the-shelf cell therapy product for muscle and tendon regeneration that can be used to enhance repair after rotator cuff surgery. There are currently no FDA-approved therapies using engineered cells for the treatment of rotator cuff injuries.

According to the American Academy of Orthopaedic Surgeons (AAOS), nearly 2 million patients in the U.S. seek help for their rotator cuff injuries. The incidence of these injuries increases with age, so as the U.S. population ages the prevalence and potential cost burden is likely to grow.

“Following the favorable results of our Phase I/II trial in our first orthopedic indication, the treatment of injured gluteal muscle after total hip replacement, we, together with Key Opinion Leaders in orthopedic surgery, selected rotator cuff repair as an important indication in need of a novel cell therapy solution. We are progressing with our study design, and are considering the addition of a third orthopedic indication,” stated Pluristem CEO Zami Aberman.

“There is a clear and unmet need for a new kind of therapy that can improve the outcome of orthopedic surgery for rotator cuff tears. Our PLX cells can be administered as a simple office procedure. The team of Key Opinion Leaders advising us is particularly excited by the potential of a non-invasive, effective cell therapy for orthopedic indications,” added Aberman.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the Company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of June the Company enrolled 19 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 54 patients were enrolled over the past three months, with 21 enrolled in April, 14 in May, and 19 in June. This marks a 93% increase over the prior three month period when a total of 28 patients were enrolled, with 8 in January, 6 in February, and 14 in March. Since the beginning of 2014, the Company has enrolled a total of 82 patients. This compares with 10 patients enrolled in the first half of 2013.

“As a result of active patient recruitment ongoing in an increasing number of clinical centers around the world, we are seeing the kind of acceleration we expect in patient enrollment numbers. With the United Kingdom having recently cleared our study, we are well past the halfway mark for country approvals. We are looking forward to receiving approvals from multiple additional countries later this year before being fully approved in all participating countries,” stated CEL-SCI Chief Executive Officer Geert Kersten.

So far, a total of 218 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

WILMINGTON, Mass., June 30, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today stated that it has shipped over $400,000 in previously unannounced orders of QS-H150s and QS-B220s to multiple customers in Asia, Europe, Africa and the Middle East. Customers for the handheld and desktop explosives trace detectors include critical infrastructure, air cargo facilities, VIP protection details, and national military organizations.

“The diversity of customers in these shipments highlights the performance and flexibility of our trace detection equipment across a broad spectrum of security needs. Most of these are new customers, and in some instances we are replacing a competitor’s equipment. Our ability to attract new customers, and displace systems from other manufacturers, are important contributors to our growing market share,” stated Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones.

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About the QS-B220 Desktop Explosives and Drugs Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

WILMINGTON, Mass., July 1, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that Todd Hauptli, President and Chief Executive Officer of the American Association of Airport Executives (AAAE) visited and toured the Company’s headquarters and manufacturing facility.

“I am really impressed with the trajectory of the company at Implant Sciences,” AAAE’s President and CEO, Todd Hauptli, commented. Hauptli reviewed the QS-B220, currently in final stages of evaluation by the TSA, which was designed to advance the state of the art in system uptime, false alarms rates, and throughput—all things that will support getting travelers through checkpoints safely and quickly. “It is clear to me that the Company has put much thought into preparing its manufacturing and support teams to provide for the rapid deployment of a large number of these systems,” said Hauptli.

The QS-B220 clears down rapidly both between samples as well as after an alarm, resulting in faster processing at checkpoints. The system’s patented inCal™ internal automatic calibration system keeps the system ready to detect without operator intervention. Push button maintenance and diagnostics mean more consistent, longer uptimes to help ensure deployed systems are available for virtually continuous use.

“We had a great visit today with Todd and we thank him for taking the time to gain a deeper understanding of our technology and the value we seek to provide to aviation security. AAAE has long been a key stakeholder in US airport security operations and policy, continually working with TSA and policy makers to optimize security while improving the experience of air travelers,” stated Implant Sciences’ President and CEO, Glenn D. Bolduc.

“Implant Sciences is committed to delivering ETD systems, such as the QS-B220, that are purpose-built to meet the needs of critical safety as well as the operational and logistical needs of airports here in the US and internationally,” Bolduc added. “With our membership in AAAE and this visit from Mr. Hauptli, we continue to gain critical input about what airports are looking for in next-generation aviation security technologies. This interaction with airport leadership is crucial to our current and future technology development.”

AAAE is the world’s largest professional organization for airport executives, representing thousands of airport management personnel at public-use commercial and general aviation airports. The organization’s members represent approximately 850 airports and hundreds of companies and organizations that support airports. AAAE is also is one of the most influential associations in Washington DC, ranking in the top 1% of professional trade associations in terms of budget and staff size with an unparalleled reputation of influence and effectiveness in Washington for their outstanding advocacy and support of airports. Implant Sciences became a member of the AAAE in January.

The AAAE’s Carter Morris recently interviewed Implant Sciences’ Chief Operating Officer Dr. Bill McGann on its program, One on One. To see the video please visit: https://www.youtube.com/watch?v=K2Rg2g_WaMs

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

BOTHELL, WA–(Marketwired – Jun 30, 2014) – Borneo Resource Investments Ltd. (OTCQB: BRNE), (the “Company” or “Borneo”) a mining company that mines gold and develops producing gold mining properties in Indonesia, today announced it is building its second processing area to extract more gold from ore at its Ratatotok South property. Borneo expects this infrastructure expansion will triple the Company’s gold production at the property.

Borneo acquired Ratatotok South, one of its three contiguous Ratatotok properties, in December 2013 through its subsidiary PT Puncak Kalabat. The 8.5 hectare property, located in the middle of a well-established gold reef area, became the Company’s second producing gold mine. Borneo started mining the property shortly after its acquisition and completed its first full production run in May 2014.

Ratatotok South’s current heap leach processing area yields 2 – 3 kilograms of gold per month from approximately 2,500 metric tons of ore. Borneo is now building its second heap leach processing area on its Ratatotok properties which will provide an additional monthly ore processing capacity of 5,000 metric tons. Upon completion of the second heap leach processing area in July, Ratatotok South is expected to have the capacity to process a total of approximately 7,500 metric tons of ore per month, yielding about 7 – 10 kilograms (245 – 350 ounces) of gold per month.

“We are pleased with how quickly we’ve ramped up production at Ratatotok South. The gold yields we’ve seen to date from the ore warrant our investment in building this second heap leach processing area, which we believe will significantly increase our production at this property and be able to serve all three of our Ratatotok properties. We anticipate beginning production at Ratatotok, and at Ratatotok Southeast, later this year,” stated Borneo CEO Nils Ollquist. “By being on-site and supervising day-to-day operations, we are producing the kind of results we want to see from our acquired properties. As we increase our number of acquired and producing properties, we are looking for meaningful scaling opportunities in the quantities of gold produced and sold.”

About Borneo Resource Investments Ltd.

Borneo Resource Investments Ltd. (OTCQB: BRNE) is a mining company that mines gold and develops producing gold mining properties as well as coal mining properties in the Republic of Indonesia. Borneo’s current assets include four gold properties, two of which are producing gold. Cash flow-producing investments in gold properties help fund Borneo’s operations and investments in gold, while the Company develops high value, longer-term investments in thermal “coal concessions,” which are properties that can be mined for coal. Borneo currently has one coal concession in the Borneo region of Indonesia. Indonesia was the 8th largest gold producing nation in 2012 and the world’s largest exporter of coal, with $25 billion exported in 2012.

EVEN YEHUDA, Israel, June 13, 2014 /PRNewswire/ —

Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), a clean energy company that develops, manages and owns waste-to-energy projects, announced today it has signed a Memorandum of Understanding (“MoU”) with a local developer operating in the recycling and compost business to co-develop a waste-to-energy project in the Boston metropolitan area.

This marks the third waste-to-energy facility in development for Bluesphere. The Company is developing a 5.2 MW facility in Charlotte, North Carolina, which is currently in its design and engineering phase and is expected to break ground on construction this year and be fully operational in 2015. The Charlotte, North Carolina facility has received over $22 million in project financing commitments from a Fortune 50 company and a leading environmental investment fund, as well as having signed a long-term contract with one of the largest power holding companies in the U.S. to purchase electricity generated at the plant. Bluesphere is also developing a 3.2 MW waste-to-energy facility in Johnston, Rhode Island.

Per the terms of the MoU, Bluesphere will take advantage of the site’s existing operations to build and operate a 5.2 MW waste-to-energy plant on the same premises in the Boston metropolitan area. The advantage of such an approach is that the joint project will benefit from the site’s existing permits and feedstock supply arrangements.

“Our partner has already developed much of the critical infrastructure for a waste-to-energy project and this is not only expected to shorten our timeline to develop the project from start to finish, it is also expected to reduce costs and increase profitability for the project,” stated Bluesphere CEO Shomi Palas.

Bluesphere generates electricity from biogas derived from organic waste, which is mostly food waste, and sells this electricity to leading electric companies through long-term power purchase agreements. Waste-to-energy is one of the fastest growing segments in the renewable energy markets. According to SBI Energy, the thermal and biological segments reached $6 billion in 2012 and will reach $29 billion by 2022.

PETACH TIKVA, Israel, June 17, 2014 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has finalized enrollment in its Phase II/III trial of CF101 for the treatment of psoriasis with over 300 patients through 17 clinical centers in the U.S., Israel and Europe. Top line results from the trial are expected in the first quarter of 2015.

The psoriasis therapeutic market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018, according to Global Data. The market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential side effects.

“Based on our studies to date, we believe that, if approved, CF101 would have the potential to offer an oral, safe and well-tolerated treatment alternative for people living with psoriasis,” stated Can-Fite CEO Dr. Pnina Fishman. “Now that we have completed patient enrollment, we hope that the upcoming conclusion of this Phase II/III trial will yield additional data which may prove the efficacy of CF101 in the treatment of psoriasis.”

About the Trial

The Phase II/III double-blind, placebo-controlled study is designed to test the efficacy of CF101 in 300 patients with moderate-to-severe plaque psoriasis. The first study cohort was comprised of three arms with patients receiving: 1 mg of CF101; 2 mg of CF101; and placebo. All patients receiving placebo were switched to either 1 mg or 2 mg of CF101 after 12 weeks. The primary efficacy endpoints are a statistically significant improvement in standard measures used by dermatologists to assess psoriasis including the Psoriasis Area Sensitivity Index (PASI) score and the Physicians’ Global Assessment (PGA) score as well as various safety parameters.

Interim safety and efficacy results were released from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of CF101 at the 2 mg dose relative to placebo were observed through PASI and PGA scores, with the responses accumulating steadily over the 24-week treatment period. To allow the trial to meet its full objectives, the study protocol has been amended to enroll patients for the 2 mg dose and placebo administration for an extended study period of 32 weeks.

HAIFA, Israel, June 19, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that Russia’s Federal Service for Intellectual Property has granted to Pluristem Patent No. 2515156 titled, “Methods of Treating Inflammatory Colon Diseases”. The patent covers methods for treating ulcerative colitis or Crohn’s disease using placenta-derived cells. This patent has already been issued to Pluristem in South Africa and is currently pending in several other jurisdictions.

“Pre-clinical studies have demonstrated that PLX cells are potentially effective in treating inflammatory bowel disease, and we may consider advancing into clinical trials with this indication in future,” stated Pluristem CEO Zami Aberman. “This patent issued in Russia is the latest in a series of patents we’ve been granted across the globe for the use of placenta-derived cell therapies in a variety of different indications.”

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a protein delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic conditions. PLX cells are grown using the Company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

HAIFA, Israel, June 16, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted Patent No. 261087 from India’s Office of the Controller General of Patents, Designs & Trade Marks for a patent titled, “Methods for Cell Expansion and Conditioned Media Produced Thereby for Therapy.”

The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company’s key technology platform, its method for 3-dimensional expansion of placental and adipose (fat) derived cells. It also covers the composition of cells derived using this method.

“We believe Pluristem is the global leader in the commercial-scale production of placenta-derived cells. In our manufacturing facility, we use proprietary 3-dimensional cell expansion technology that gives us the ability to precisely control cell growth based on the intended indication to be treated. Our ability to do this on a large scale is one of our key assets,” stated Pluristem CEO Zami Aberman.

“This patent issued by India is an important part of our global IP strategy to protect our breakthrough cell production methods in high-value and emerging healthcare markets where we see future potential for growth,” Aberman added.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the Company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

EVEN YEHUDA, Israel, June 11, 2014 /PRNewswire/ —

Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), a clean energy company that develops, manages and owns waste-to-energy projects, announced today it is pursuing a strategy to acquire fully operational, revenue generating waste-to-energy facilities in select global markets. The Company is augmenting its current build-own-operate model with an acquirer-own-operate strategy in order to create immediate revenue and cash flow generation, putting the Company on a short term path to profitability in the $6 billion global waste-to-energy market.

Bluesphere is currently conducting due diligence on an acquisition opportunity in Italy for 16 anaerobic digestion waste-to-energy 1 MW facilities that have each been fully operational for at least a year. These facilities have long term agreements with local utilities that are purchasing electricity from the plants. Based on due diligence conducted to date, collectively the plants are producing very high EBITDA, are expected to have an internal rate of return (IRR) of greater than 25%, and if acquired, would generate strong immediate cash for Bluesphere.

“By executing on this acquisition strategy, we believe we are accelerating our timeline to significant revenues, EBITDA and profitability, while also reducing risk by acquiring facilities that have a track record of consistent operational performance. The acquisition opportunity in Italy serves as model for Bluesphere’s future acquisitions as we pursue a tremendous global opportunity in the organic waste-to-energy market,” stated Bluesphere CEO Shlomi Palas.

Bluesphere is currently developing two facilities in the U.S. under its build-own-operate model. The first is a 5.2 MW facility in Charlotte, North Carolina slated to become fully operational in 2015. Approximately $23 million in project financing has been secured from a Fortune 50 company and a leading environmental finance fund. One of the largest power holding companies in the U.S. has signed a long-term contract with Bluesphere to purchase electricity generated at the Charlotte plant.

About Bluesphere Corporation

Bluesphere Corporation is a company in the cleantech sector as a waste-to-energy project integrator. Bluesphere develops waste-to-energy and other renewable energy projects. The Company aspires to become a key player in the global waste-to-energy and renewable energy markets. For further information please visit the Company’s website http://www.bluespherecorporate.com